ABIVAX_Logo-RGB.png
Abivax Provides Operational and Key Program Update
15 juil. 2024 16h00 HE | Abivax
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1...
ABIVAX_Logo-RGB.png
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
04 juin 2024 16h10 HE | Abivax
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the...
ABIVAX_Logo-RGB.png
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
08 mai 2024 02h30 HE | Abivax
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST –...
ABIVAX_Logo-RGB.png
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
07 mai 2024 16h00 HE | Abivax
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 Availability of the preparatory documents PARIS, France, May 7, 2024, 10:00PM CEST – Abivax SA (Euronext Paris & Nasdaq:...
ABIVAX_Logo-RGB.png
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
05 avr. 2024 16h00 HE | Abivax
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or...
ABIVAX_Logo-RGB.png
Abivax reports 2023 financial results and operational update
02 avr. 2024 02h30 HE | Abivax
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and...
ABIVAX_Logo-RGB.png
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
07 févr. 2024 02h30 HE | Abivax
Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a...
ABIVAX_Logo-RGB.png
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
02 févr. 2024 02h30 HE | Abivax
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December...
ABIVAX_Logo-RGB.png
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
24 janv. 2024 02h30 HE | Abivax
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS,...
ABIVAX_Logo-RGB.png
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
22 janv. 2024 02h30 HE | Abivax
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in...